Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM)

被引：0

作者：

Schuchter, Lynn Mara

Kudchadkar, Ragini Reiney

Gonzalez, Rene

Lawrence, Donald P.

Sosman, Jeffrey Alan

Infante, Jeffrey R.

Daud, Adil

Kefford, Richard

Cebon, Jonathan S.

Sharfman, William Howard

Amaravadi, Ravi K.

Boasberg, Peter D.

Lewis, Karl D.

Flaherty, Keith

Ouellet, Danielle

Little, Shonda M.

Clark, Jennifer

Gibney, Geoffrey Thomas

Patel, Kiran

Hamid, Omid

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[3] UCHSC, Aurora, CO USA

[4] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[6] Sarah Cannon Res Inst, Nashville, TN USA

[7] Tennessee Oncol, Nashville, TN USA

[8] Univ Calif San Francisco, San Francisco, CA 94143 USA

[9] Westmead Hosp, Westmead, NSW 2145, Australia

[10] Melanoma Inst Australia, Westmead, NSW, Australia

[11] Austin Hlth, Melbourne, Vic, Australia

[12] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[13] Angeles Clin & Res Inst, Santa Monica, CA USA

[14] Univ Colorado, Ctr Canc, Aurora, CO USA

[15] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA

[16] GlaxoSmithKline, Res Triangle Pk, NC USA

[17] GlaxoSmithKline, Collegeville, PA USA

[18] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9066

引用

页数：1

共 37 条

[21] Retrospective analysis of safety in elderly BRAF V600 mutation-positive advanced melanoma patients treated with dabrafenib (D) and trametinib (T) and correlation with non-elderly patients
Garcia-Castano, A.
Gonzalez-Barrallo, I.
Castellon Rubio, V. E.
Medina Martinez, J.
Manzano Mozo, J. L.
Mujika, K.
Majem Tarruella, M.
Aguado de La Rosa, C.
Cabrera Suarez, M. A.
Palacio, I.
Osterloh, L.
Martinez Fernandez, A.
ANNALS OF ONCOLOGY, 2020, 31 : S753 - S753
[22] Phase 1 trial of MEK1 inhibitor E6201 plus dabrafenib in patients (pts) with BRAF V600-mutated metastatic melanoma (MM) with central nervous system (CNS) metastases (mets)
Seetharam, Mahesh
Dronca, Roxana
Dudek, Arkadiusz Z.
Nelson, Garth
Block, Matthew
Starling, Skylar
Baskin, Amber
Bradshaw, Renee
Nelson, Courtney
Andrews, Kylee
Birgin, Alisha
Watson, Cristina
Yan, Yiyi
Mahadevan, Daruka
Markovic, Svetomir
Myers, Tom
Paradiso, Linda
Babiker, Hani
CANCER RESEARCH, 2024, 84 (07)
[23] Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).
Bendell, Johanna C.
Atreya, Chloe Evelyn
Andre, Thierry
Tabernero, Josep
Gordon, Michael S.
Bernards, Rene
Van Cutsem, Eric
Tejpar, Sabine
Sidhu, Roger
Go, William Y.
Allred, Alicia
Motwani, Monica
Suttle, Benjamin B.
Wu, Yuehui
Hoos, Axel
Orford, Keith W.
Corcoran, Ryan Bruce
Schellens, Jan H. M.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[24] Safety and preliminary activity data from a single center phase II study of triplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [trident] in patients (Pts) with BRAF-mutated metastatic melanoma (MM).
Tawbi, Hussein Abdul-Hassan
Amaria, Rodabe Navroze
Glitza, Isabella Claudia
Milton, Denai
Hwu, Wen-Jen
Patel, Sapna Pradyuman
Wong, Michael K. K.
Yee, Cassian
Woodman, Scott Eric
McQuade, Jennifer Leigh
Hwu, Patrick
Perdon, Karen Mae
Shephard, Michael
Burton, Elizabeth M.
Wargo, Jennifer Ann
Davies, Michael A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[25] Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical outcome in BRAF V600 mutation-positive melanoma patients (pts) treated with the MEK inhibitor trametinib (T) or chemotherapy (C)
Schadendorf, Dirk
Flaherty, Keith
Hersey, Peter
Nathan, Paul D.
Garbe, Claus
Milhem, Mohammed M.
Demidov, Lev V.
Hassel, Jessica Cecile
Rutkowski, Piotr
Mohr, Peter
Dummer, Reinhard
Trefzer, Uwe
Larkin, James M. G.
Utikal, Jochen
Casey, Michelle
Santiago-Walker, Ademi
Sherman, Laurie Jill
Martin, Anne-Marie
Wu, Frank S.
Robert, Caroline
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[26] Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma
Weber, Jeffrey S.
Flaherty, Keith T.
Infante, Jeffrey R.
Falchook, Gerald Steven
Kefford, Richard
Daud, Adil
Hamid, Omid
Gonzalez, Rene
Kudchadkar, Ragini Reiney
Lawrence, Donald P.
Burris, Howard A.
Long, Georgina V.
Algazi, Alain Patrick
Lewis, Karl D.
Kim, Kevin B.
Puzanov, Igor
Sun, Peng
Little, Shonda M.
Patel, Kiran
Sosman, Jeffrey Alan
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[27] Safety and effectiveness analysis of V600 BRAF-mutated metastatic melanoma (MM) patients (pts) from the dabrafenib (D) plus trametinib (T) named patient programme (NPP) - DESCRIBE II study
Atkinson, V.
Thienen, J. V.
McArthur, G.
Hospers, G.
Long, G.
Carnevale-Schianca, F.
Tulyte, S.
Stein, D.
Bassel, M.
Freivogel, K.
Dalland, L.
Lau, M.
Legenne, P.
Ferrucci, P. F.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S677 - S678
[28] Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
Long, Georgina V.
Stroyakovskiy, Daniil
Gogas, Helen
Levchenko, Evgeny
De Braud, Filippo G.
Larkin, James M. G.
Garbe, Claus
Jouary, Thomas
Hauschild, Axel
Grob, Jean Jacques
Chiarion-Sileni, Vanna
Lebbe, Celeste
Mandala, Mario
Millward, Michael
DeMarini, Douglas James
Irani, Jhangir G.
Jin, Fan
Swann, R. Suzanne
Mookerjee, Bijoyesh
Flaherty, Keith
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[29] Phase II Study of TRIplet combination Nivolumab (N) with Dabrafenib (D) and Trametinib (T) (TRIDeNT) in patients (pts) with PD-1 naive or refractory BRAF-mutated metastatic melanoma (MM) with or without active brain metastases.
Burton, Elizabeth M.
Amaria, Rodabe Navroze
Glitza, Isabella Claudia
Milton, Denai R.
Diab, Adi
Patel, Sapna Pradyuman
McQuade, Jennifer Leigh
Honaker, Virginia
Wong, Michael K. K.
Hwu, Patrick
Wargo, Jennifer Ann
Davies, Michael A.
Tawbi, Hussein Abdul-Hassan
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[30] The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I
Long, Georgina V.
Lebbe, Celeste
Atkinson, Victoria
Mandala, Mario
Nathan, Paul D.
Arance, Ana
Richtig, Erika
Yamazaki, Naoya
Robert, Caroline
Schadendorf, Dirk
Tawbi, Hussein Abdul-Hassan
Ascierto, Paolo Antonio
Ribas, Antoni
Flaherty, Keith
Lee, Dung-Yang
Masood, Aisha
Gasal, Eduard
Dummer, Reinhard
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)

← 1 2 3 4 →